questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines membranaires
Récepteurs de surface cellulaire
Récepteurs peptidiques
Récepteur facteur croissance
Récepteurs facteur croissance nerf
Récepteur facteur neurotrophique ciliaire
Récepteur facteur neurotrophique ciliaire : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Récepteur facteur neurotrophique ciliaire : Questions médicales les plus fréquentes",
"headline": "Récepteur facteur neurotrophique ciliaire : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Récepteur facteur neurotrophique ciliaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-06",
"dateModified": "2025-04-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Récepteur facteur neurotrophique ciliaire"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Récepteurs facteur croissance nerf",
"url": "https://questionsmedicales.fr/mesh/D017475",
"about": {
"@type": "MedicalCondition",
"name": "Récepteurs facteur croissance nerf",
"code": {
"@type": "MedicalCode",
"code": "D017475",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.750.750.400.550"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Sous-unité alpha du récepteur du facteur neurotrophique ciliaire",
"alternateName": "Ciliary Neurotrophic Factor Receptor alpha Subunit",
"url": "https://questionsmedicales.fr/mesh/D053739",
"about": {
"@type": "MedicalCondition",
"name": "Sous-unité alpha du récepteur du facteur neurotrophique ciliaire",
"code": {
"@type": "MedicalCode",
"code": "D053739",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.750.750.400.550.250.249"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Récepteur gp130 de cytokines",
"alternateName": "Cytokine Receptor gp130",
"url": "https://questionsmedicales.fr/mesh/D050822",
"about": {
"@type": "MedicalCondition",
"name": "Récepteur gp130 de cytokines",
"code": {
"@type": "MedicalCode",
"code": "D050822",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.750.750.400.550.250.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Sous-unité alpha du récepteur au facteur d'inhibition de la leucémie",
"alternateName": "Leukemia Inhibitory Factor Receptor alpha Subunit",
"url": "https://questionsmedicales.fr/mesh/D053680",
"about": {
"@type": "MedicalCondition",
"name": "Sous-unité alpha du récepteur au facteur d'inhibition de la leucémie",
"code": {
"@type": "MedicalCode",
"code": "D053680",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.750.750.400.550.250.750"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Récepteur facteur neurotrophique ciliaire",
"alternateName": "Receptor, Ciliary Neurotrophic Factor",
"code": {
"@type": "MedicalCode",
"code": "D020801",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Giovanni Tossetta",
"url": "https://questionsmedicales.fr/author/Giovanni%20Tossetta",
"affiliation": {
"@type": "Organization",
"name": "Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy."
}
},
{
"@type": "Person",
"name": "Antonio Giordano",
"url": "https://questionsmedicales.fr/author/Antonio%20Giordano",
"affiliation": {
"@type": "Organization",
"name": "Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy."
}
},
{
"@type": "Person",
"name": "Cuihong Jia",
"url": "https://questionsmedicales.fr/author/Cuihong%20Jia",
"affiliation": {
"@type": "Organization",
"name": "Department of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA. Electronic address: jiac01@etsu.edu."
}
},
{
"@type": "Person",
"name": "Theo Hagg",
"url": "https://questionsmedicales.fr/author/Theo%20Hagg",
"affiliation": {
"@type": "Organization",
"name": "Department of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA."
}
},
{
"@type": "Person",
"name": "Jessica Perugini",
"url": "https://questionsmedicales.fr/author/Jessica%20Perugini",
"affiliation": {
"@type": "Organization",
"name": "Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Impact of cholangitis on survival of patients with malignant biliary obstruction treated with percutaneous transhepatic biliary drainage.",
"datePublished": "2023-03-27",
"url": "https://questionsmedicales.fr/article/36973653",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12876-023-02704-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "ERCP-Related Adverse Events in Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis.",
"datePublished": "2022-07-21",
"url": "https://questionsmedicales.fr/article/35910039",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/2372257"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cholangitis with Sphingobacterium multivorum and Acinetobacter junii bacteremia in a patient with gastric cancer: A case report.",
"datePublished": "2022-06-16",
"url": "https://questionsmedicales.fr/article/35718261",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jiac.2022.06.005"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hepatic reactive lymphoid hyperplasia-associated primary biliary cholangitis masquerading as a neoplastic liver lesion.",
"datePublished": "2023-11-15",
"url": "https://questionsmedicales.fr/article/37967929",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bcr-2023-254963"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Predictive Value of Different Laboratory Indicators Based on the 2018 Tokyo Guidelines for the Severity of Acute Cholangitis.",
"datePublished": "2023-06-05",
"url": "https://questionsmedicales.fr/article/37673776",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jemermed.2023.05.013"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Récepteurs de surface cellulaire",
"item": "https://questionsmedicales.fr/mesh/D011956"
},
{
"@type": "ListItem",
"position": 6,
"name": "Récepteurs peptidiques",
"item": "https://questionsmedicales.fr/mesh/D018000"
},
{
"@type": "ListItem",
"position": 7,
"name": "Récepteur facteur croissance",
"item": "https://questionsmedicales.fr/mesh/D017978"
},
{
"@type": "ListItem",
"position": 8,
"name": "Récepteurs facteur croissance nerf",
"item": "https://questionsmedicales.fr/mesh/D017475"
},
{
"@type": "ListItem",
"position": 9,
"name": "Récepteur facteur neurotrophique ciliaire",
"item": "https://questionsmedicales.fr/mesh/D020801"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Récepteur facteur neurotrophique ciliaire - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Récepteur facteur neurotrophique ciliaire",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Récepteur facteur neurotrophique ciliaire",
"description": "Comment diagnostiquer une dysfonction du récepteur CNTF ?\nQuels examens sont utilisés pour évaluer le récepteur CNTF ?\nY a-t-il des biomarqueurs pour le récepteur CNTF ?\nLe diagnostic nécessite-t-il une biopsie ?\nQuels symptômes peuvent indiquer un problème avec le CNTF ?",
"url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=6#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Récepteur facteur neurotrophique ciliaire",
"description": "Quels sont les symptômes d'une déficience en CNTF ?\nLa douleur neuropathique est-elle liée au CNTF ?\nPeut-on observer des troubles moteurs avec le CNTF ?\nLes troubles sensoriels sont-ils associés au CNTF ?\nY a-t-il des signes cliniques spécifiques au CNTF ?",
"url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=6#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Récepteur facteur neurotrophique ciliaire",
"description": "Peut-on prévenir les troubles liés au CNTF ?\nY a-t-il des mesures préventives spécifiques ?\nL'exercice régulier aide-t-il à prévenir les troubles du CNTF ?\nUne alimentation équilibrée peut-elle aider ?\nLe stress a-t-il un impact sur le CNTF ?",
"url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=6#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Récepteur facteur neurotrophique ciliaire",
"description": "Quels traitements sont disponibles pour les troubles du CNTF ?\nLes thérapies géniques peuvent-elles aider le CNTF ?\nLes médicaments anti-inflammatoires sont-ils efficaces ?\nLa physiothérapie est-elle recommandée ?\nY a-t-il des traitements expérimentaux pour le CNTF ?",
"url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=6#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Récepteur facteur neurotrophique ciliaire",
"description": "Quelles complications peuvent survenir avec le CNTF ?\nLe CNTF peut-il entraîner des troubles cognitifs ?\nY a-t-il un risque de dépendance aux médicaments ?\nLes complications sont-elles réversibles ?\nLe CNTF peut-il affecter la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=6#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Récepteur facteur neurotrophique ciliaire",
"description": "Quels sont les facteurs de risque pour les troubles du CNTF ?\nL'âge est-il un facteur de risque pour le CNTF ?\nLe sexe influence-t-il le risque de troubles du CNTF ?\nLes infections peuvent-elles augmenter le risque ?\nLe mode de vie influence-t-il le risque de troubles ?",
"url": "https://questionsmedicales.fr/mesh/D020801?mesh_terms=Cholangitis&page=6#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction du récepteur CNTF ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests neurologiques et des analyses génétiques."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour évaluer le récepteur CNTF ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des IRM et des électromyogrammes peuvent être utilisés pour évaluer la fonction nerveuse."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs pour le récepteur CNTF ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de biomarqueurs spécifiques pour le récepteur CNTF."
}
},
{
"@type": "Question",
"name": "Le diagnostic nécessite-t-il une biopsie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une biopsie n'est généralement pas nécessaire pour diagnostiquer les troubles liés au CNTF."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec le CNTF ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la faiblesse musculaire ou des douleurs neuropathiques peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en CNTF ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent faiblesse musculaire, douleurs chroniques et troubles sensoriels."
}
},
{
"@type": "Question",
"name": "La douleur neuropathique est-elle liée au CNTF ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le CNTF joue un rôle dans la modulation de la douleur neuropathique."
}
},
{
"@type": "Question",
"name": "Peut-on observer des troubles moteurs avec le CNTF ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles moteurs peuvent survenir en raison d'une dysfonction du CNTF."
}
},
{
"@type": "Question",
"name": "Les troubles sensoriels sont-ils associés au CNTF ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles sensoriels peuvent être observés en cas de dysfonction du CNTF."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cliniques spécifiques au CNTF ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme l'hypersensibilité ou l'engourdissement peuvent être spécifiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés au CNTF ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les traumatismes nerveux et gérer les maladies chroniques peut aider."
}
},
{
"@type": "Question",
"name": "L'exercice régulier aide-t-il à prévenir les troubles du CNTF ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut renforcer les muscles et améliorer la santé nerveuse."
}
},
{
"@type": "Question",
"name": "Une alimentation équilibrée peut-elle aider ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en nutriments favorise la santé nerveuse et musculaire."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur le CNTF ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter la fonction nerveuse et aggraver les symptômes."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles du CNTF ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des thérapies médicamenteuses et des interventions physiques."
}
},
{
"@type": "Question",
"name": "Les thérapies géniques peuvent-elles aider le CNTF ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur l'utilisation de thérapies géniques pour cibler le CNTF."
}
},
{
"@type": "Question",
"name": "Les médicaments anti-inflammatoires sont-ils efficaces ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent réduire l'inflammation et améliorer les symptômes liés au CNTF."
}
},
{
"@type": "Question",
"name": "La physiothérapie est-elle recommandée ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la physiothérapie peut aider à améliorer la fonction musculaire et réduire la douleur."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux pour le CNTF ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements expérimentaux, comme les thérapies biologiques, sont en cours d'évaluation."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le CNTF ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent la progression des troubles neurologiques et la douleur chronique."
}
},
{
"@type": "Question",
"name": "Le CNTF peut-il entraîner des troubles cognitifs ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles cognitifs peuvent survenir en raison de la dysfonction du CNTF."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque de dépendance aux médicaments ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements peuvent entraîner une dépendance, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Le CNTF peut-il affecter la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les troubles liés au CNTF peuvent significativement affecter la qualité de vie."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles du CNTF ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des maladies auto-immunes et des traumatismes."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour le CNTF ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de troubles liés au CNTF augmente avec l'âge."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque de troubles du CNTF ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines études montrent que le sexe peut influencer le risque de troubles."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles augmenter le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections peuvent déclencher des troubles liés au CNTF."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque de troubles ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque."
}
}
]
}
]
}
To evaluate the impact of cholangitis on survival of patients with gastrointestinal cancer and malignant biliary obstruction treated with percutaneous transhepatic biliary drainage (PTBD)....
A retrospective registry study was performed at a tertiary center from 2000 to 2016 in Northern Finland....
The study included 588 patients, 258 (43.9%) patients with pancreatic cancer, 222 (37.7%) with biliary tract cancer, and 108 (18.4%) with metastasis from gastrointestinal cancers. Patient mean age was...
In gastrointestinal cancers with malignant biliary obstruction, survival is poorer if cholangitis occurs before PTBD compared to cholangitis after PTBD. An oncologist's consultation is essential for a...
While endoscopic retrograde cholangiopancreatography (ERCP) is a valuable diagnostic and therapeutic tool in primary sclerosing cholangitis (PSC), there is conflicting data on associated adverse event...
Embase, PubMed, and CENTRAL were searched between January 1, 2000, and May 12, 2021. Eligible studies included adults with PSC undergoing ERCP and reported at least one ERCP-related adverse event (cho...
Twenty studies met eligibility criteria, of which four were included in a meta-analysis comparing post-ERCP adverse events in patients with PSC (...
In the context of limited comparative data and heterogeneity, PSC patients undergoing ERCP have higher odds of cholangitis despite the majority receiving antibiotics. Additionally, accidental wire pas...
Sphingobacterium is an aerobic, glucose non-fermenting, Gram-negative rod bacterium that has been isolated from soil, plants, food, and water sources, including in hospitals. Reports of systemic infec...
A 68-year-old woman with advanced gastric cancer, hypertension, and hyperlipidemia was admitted with obstructive jaundice, and subsequently developed obstructive cholangitis during the hospital stay. ...
S. multivorum infection is rare, and its microbiology and pathogenicity in humans is mostly unknown. Therefore, multiple diagnostic approaches should be used to identify S. multivorum, and antimicrobi...
Hepatic reactive lymphoid hyperplasia is an uncommon benign condition, often found incidentally as a solitary liver lesion. The chronic inflammatory reaction associated with autoimmune conditions and ...
This study evaluated the predictive value of different laboratory indicators for the severity of acute cholangitis (AC) according to the 2018 Tokyo Guidelines....
We enrolled consecutive patients with a diagnosis of AC from June 2016 to May 2021. Serum procalcitonin (PCT) and C-reactive protein (CRP) levels, white blood cell counts, the neutrophil-lymphocyte ra...
In total, 293 patients were enrolled in this study (mild, n = 172; moderate, n = 68; severe, n = 53). In receiver operating characteristic analyses, CRP was the best biomarker for differentiating mild...
PCT can be used as a reliable predictor of severe AC. CRP was most predictive of moderate AC, whereas PLR was most predictive of blood culture positivity....
In patients with obstructive pancreatitis due to choledocholithiasis, endoscopic retrograde cholangiopancreatography (ERCP) is the standard of care. ERCP-induced inflammation or infection of the commo...
The role and optimal timing of endoscopic retrograde cholangiopancreatography (ERCP) in acute biliary pancreatitis without cholangitis (ABPwoC) remains unclear. Using a large national database, we aim...
This was a retrospective study of adult patients with ABPwoC utilizing the National Inpatient Sample from 2016-2017. Patients who underwent inpatient ERCP were stratified into performance: within 24, ...
Of the 70 030 patients with ABPwoC, 31.37% underwent inpatient ERCP. Performance (aOR: 0.6, p < .05), but not timing (aOR: 0.98, p = .9), of inpatient ERCP was associated with significantly lower all-...
Based on this large, nationwide analysis, inpatient ERCP for ABPwoC is associated with lower all-cause mortality. ERCP within 24 and 72 h, though not associated with lower mortality, are associated wi...
Primary biliary cholangitis (PBC) patients often have concomitant extrahepatic autoimmune (EHA) diseases including Sjögren's syndrome (SS), systemic sclerosis (SSc), rheumatoid arthritis (RA), and aut...
Medical records of PBC patients diagnosed in our institute were retrospectively reviewed. Patients were followed up by a standardized telephone interview. The endpoints were defined as liver-related d...
Totally 247 of the 985 (25.1%) PBC patients enrolled in the study had at least one concomitant EHA disease. Sjögren's syndrome (n = 140, 14.2%) was the most frequent one, followed by rheumatoid arthri...
Concomitant EHA diseases were common in PBC patients but did not compromise the long-term outcomes of PBC....
Anti-mitochondrial antibody (AMA)-associated myopathies represent a homogeneous disease entity with severe arrhythmia and slowly progressive proximal muscle weakness with lordotic posture, irrespectiv...
Gallstone disease is common worldwide and can lead to severe complications, including cholangitis; thus, it is important to identify modifiable risk factors for cholangitis. Proton pump inhibitors (PP...
This retrospective multicenter study included all patients arriving to the hospital over a 10-year period with various presentations of choledocholithiasis. We compared active PPI use in two groups: t...
Overall, 811 patients were included, 161 in group A and 650 in group B. The average age ± standard deviation (SD) in groups A and B was 74.5 ± 20.6 vs. 61.6 ± 20.9 years, respectively. PPI use in grou...
Active PPI use was associated with a higher rate of cholangitis among patients with choledocholithiasis. We advocate considering this risk before prescribing PPIs to patients with gallstones....
NHR-0263-20 received on 14/01/2021 date 'retrospectively registered'....